RSV information from the AAP
If you have questions about RSV, you can submit them here and a National staff member will follow up with you: Nirsevimab Question/Issue Submission Form
Share Feedback on RSV and Administration of Beyfortus
As we approach the 2024-25 fall respiratory virus season, the AAP is interested in learning more from chapter leaders and chapter executive directors about successes and barriers to administering Beyfortus in hospital and ambulatory settings. Information will inform the Academy's ongoing advocacy efforts. Please share feedback through the Nirsevimab Question/Issue Submission Form. We look forward to hearing from you.
Pre-recorded Webinar Series: Respiratory Virus Season 2024-2025
This new 2-part webinar series on Red Book® Online (RBO) presented by Sean T. O’Leary, MD, MPH, FAAP, Chair, AAP Committee on Infectious Diseases, provides essential information on immunization recommendations and updates to prepare for respiratory virus season. To view these webinars, as well as related resources, please visit the newly redesigned Red Book Online Webinars page.
- COVID-19 Vaccine Update (13 min)
This webinar discusses AAP COVID-19 vaccine recommendations for 2024-2025. Learn about COVID-19 hospitalization and mortality data in children, as well as vaccine safety, effectiveness, coverage rates, pediatric provider recommendations, and parental attitudes.
- RSV Immunization Update (11 min)
This webinar discusses AAP nirsevimab recommendations and administration timing, as well as the effectiveness of nirsevimab against RSV-associated emergency department visits and hospitalizations during the 2023-2024 RSV season.
RSV Immunization Guidance Not Changing; AAP Continues Work on Logistical Hurdles
The AAP recommends all infants be protected from respiratory syncytial virus (RSV) by receiving nirsevimab or through vaccination of their pregnant parent with RSVpreF (Abrysvo), and is reminding clinicians to review the clinical guidance, which will remain the same. AAP experts are optimistic the use of nirsevimab will be smoother in the upcoming season, although some logistical hurdles remain. Read more in AAP News, and please use the AAP Nirsevimab Question/Issue reporting form to submit questions, successes, and barriers related to nirsevimab administration.
Communicating with Families and Promoting Vaccine Confidence
https://www.aap.org/en/patient-care/immunizations/communicating-with-families-and-promoting-vaccine-confidence/
|